Close Menu

Lung Cancer

News and reporting on lung cancer.

The Chinese company is branching out from its core genomics business to liquid biopsy cancer screening and monitoring as it eyes areas for global expansion.

The Chinese company reported revenues of RMB112.0 million ($16.5 million), driven by growth in sales of both its LDT services and IVD products.

Veracyte reported total Q3 revenues of $31.1 million compared to $31.0 million in Q3 2019, beating analysts' average of $23.9 million.

Shares of the Boulder, Colorado-based firm will begin trading on the Nasdaq today under ticker symbol "BDSX" at $18 per share.

Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.

The assay will include a multiplexed panel of established and emerging biomarkers and will be the first RNA-based assay on the Idylla platform using FFPE samples. 

The firm intends to commercialize a probe that includes exhaled limonene and other biomarkers to enable clinicians to better identify disease stages.

The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.

The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.

The goal of the project is to build a liquid biopsy-based early detection technology platform and develop tests for lung and digestive system cancers.

Pages